Richard Zwicky spoke with Dr. Joseph Tucker, CEO of Enveric Biosciences about their development of non-hallucinogenic neuroplastogens, inspired by psychedelic research, to stimulate neuroplasticity for therapeutic benefits.

Dr. Tucker explained the distinction from psychedelics, the potential for regular use due to a shorter duration of effect, and the challenges in translating psychedelic treatments.

They also discussed the application to PTSD, integration into the mental health landscape with potential for greater accessibility and cost-effectiveness, the timeline for clinical trials aiming for market availability in the early 2030s, and the future of mental health treatment where both approaches could coexist.